Risk Factors of Treatment-Limiting Anemia after Substitution of Zidovudine for Stavudine in HIV-Infected Adult Patients on Antiretroviral Treatment

PLoS ONE

Volumn 8, Issue 3, 2013, Pages

  Phe, Thong ^a   Thai, Sopheak ^a   Veng, Chhunheng ^a   Sok, Sopheak ^a   Lynen, Lutgarde ^b   van Griensven, Johan ^a,b  

^a Sihanouk Hospital Center of HOPE   (Cambodia)

^b INSTITUTE OF TROPICAL MEDICINE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN; STAVUDINE; ZIDOVUDINE;

ADULT; AGE; ANEMIA; ARTICLE; BODY WEIGHT; CAMBODIA; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEMOGLOBIN BLOOD LEVEL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; RETROSPECTIVE STUDY; RISK FACTOR; SIDE EFFECT;

ADULT; ANEMIA; ANTI-HIV AGENTS; FEMALE; HIV INFECTIONS; HUMANS; MALE; RETROSPECTIVE STUDIES; RISK FACTORS; STAVUDINE; ZIDOVUDINE;

EID: 84875444351     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0060206     Document Type: Article

References (25)

1. World Health Organization (2011) Global HIV/AIDS Response: Epidemic Update and health sector progress toward universal access. Progress Report, Geneva. Available: http://www.who.int/hiv/pub/progress_report2011/en/.
2. Zhou J, Jaquet A, Bissagnene E, Musick B, Wools-Kaloustian K, et al. (2012) Short-term risk of anaemia following initiation of combination antiretroviral treatment in HIV-infected patients in countries in sub-Saharan Africa, Asia-Pacific, and central and South America. J Int AIDS Soc 15: 5 doi:10.1186/1758-2652-15-5.
3. World Health Organization (2010) Antiretroviral therapy for HIV infection in adults and adolescents, Recommendations for a public health approach. Geneva, ed 2010 revision. Available: http://whqlibdoc.who.int/publications/2010/9789241599764_eng.pdf.
4. Willig JH, Echevarria J, Westfall AO, Iglesias D, Henostroza G, et al. (2010) Durability of initial antiretroviral therapy in a resource-constrained setting and the potential need for zidovudine weight-based dosing. J Acquir Immune Defic Syndr 53: 215-221.
5. Cressey TR, Leenasirimakul P, Jourdain G, Tawon Y, Sukrakanchana PO, et al. (2006) Intensive pharmacokinetics of zidovudine 200 mg twice daily in HIV-1-infected patients weighing less than 60 kg on highly active antiretroviral therapy. J Acquir Immune Defic Syndr 42: 387-389.
6. Sungkanuparph S, Techasathit W, Utaipiboon C, Chasombat S, Bhakeecheep S, et al. (2010) Thai national guidelines for antiretroviral therapy in HIV-1 infected adults and adolescents 2010. Asian Biomedicine 4: 515-528.
7. Norrby SR, Gotzsche PC, Melander H, Anderson P, Lifidevirta J, et al. (1992) Double blind dose-response study of zidovudine in AIDS and advanced HIV infection. BMJ 304: 13-17.
8. Huffam SE, Srasuebkul P, Zhou J, Calmy A, Saphonn V, et al. (2007) Prior antiretroviral therapy experience protects against zidovudine-related anaemia. HIV Med 8: 465-471.
9. Toeung PD, Pov S, Chel S, Huffam S, Khol V, et al. (2007) Routine switch after 6 months from D4T to ZDV containing antiretroviral therapy, at an outpatient HIV clinic in Phnom Penh, Cmbodia. Fourth IAS Conference on HIV pathogenesis, treatment and pervention, July 22-25, 2007 Syney, Australia, WePeB059.
10. Agarwal D, Chakravarty J, Chaube L, Rai M, Agrawal NR, et al. (2010) High incidence of zidovudine induced anaemia in HIV infected patients in eastern India. Indian J Med Res 132: 386-389.
11. Kumarasamy N, Venkatesh KK, Devaleenol B, Saghayam S, Manohar D, et al. (2009) Safe substitution to zidovudine among HIV-infected patients initiated on stavudine-containing highly active antiretroviral therapy from a resource-limited setting. Int J Infect Dis 13: e360-e364.
12. Bastard JP, Soulie C, Fellahi S, Haim-Boukobza S, Simon A, et al. (2012) Circulating interleukin-6 levels correlate with residual HIV viraemia and markers of immune dysfunction in treatment-controlled HIV-infected patients. Antivir Ther 17: 915-919.
13. Lichtfuss GF, Cheng WJ, Farsakoglu Y, Paukovics G, Rajasuriar R, et al. (2012) Virologically suppressed HIV patients show activation of NK cells and persistent innate immune activation. J Immunol 189: 1491-1499.
14. Isaakidis P, Raguenaud ME, Phe T, Khim SA, Kuoch S, et al. (2008) Evaluation of a systematic substitution of zidovudine for stavudine-based HAART in a program setting in rural Cambodia. J Acquir Immune Defic Syndr 49: 48-54.
15. Cambodian Ministry of Health (2005) National Guidelines for the use of Antiretroviral Therapy in Adults and Adolescents, National Center for HIV/AIDS, Dermatology and STD, 2005 ed NCHADS.
16. Cambodian Ministry of Health (2012) National Guidelines for the use of Antiretroviral Therapy inn Adults and Adolescents, National Center for HIV/AIDS, Dermatology and STD, 2nd Revision.
17. Phan V, Thai S, Choun K, Lynen L, van Griensven J, (2012) Incidence of treatment-limiting toxicity with stavudine-based antiretroviral therapy in Cambodia: a retrospective cohort study. PLoS One 7: e30647 doi: 10.1371/journal.pone.0030647.
18. World Health Organization (2004) Scaling up Antiretroviral Therapy in Resource-limited settings: Treatment Guidelines for a Public Health Approach, ed 2003 Revision. Available: http://www.who.int/hiv/pub/prev_care/en/arvrevision2003en.pdf.
19. Sok S, Koole O, Thai S, Un P, Phan V, et al. (2009) Five years experience with an eletronic database for an ART program in Sihanouk Hospital Center of HOPE, Phnom Penh, Cambodia. 5th IAS Conference on HIV Pathogenesis and Treatment and Prevention, Captown, South Africa; [TuPeD155].
20. Mathieu R (2012) Safety of Reduced Dose Zidovudine (AZT) Compared With Standard Dose AZT in Antiretroviral-naïve HIV-infected Patients (AZTlowdose); University Hospital of Geneva; Clinical Trial N° NCT01540240. Available: http://clinicaltrials.gov/ct2/show/NCT01540240?term=azt&rank=1. Accessed 12 October, 2012.
21. van Griensven J, Un P, Phe T, Thai S, Lynen L, (2009) Substituting nevirapine for efavirenz: risk factors for toxicity in nonnaive patients in a resource-constrained setting. AIDS 23: 2374-2376.
22. Kesselring AM, Wit FW, Sabin CA, Lundgren JD, Gill MJ, et al. (2009) Risk factors for treatment-limiting toxicities in patients starting nevirapine-containing antiretroviral therapy. AIDS 23: 1689-99.
23. Ssali F, Stohr W, Munderi P, Reid A, Walker AS, et al. (2006) Prevalence, incidence and predictors of severe anaemia with zidovudine-containing regimens in African adults with HIV infection within the DART trial. Antivir Ther 11: 741-749.
24. Moh R, Danel C, Sorho S, Sauvageot D, Anzian A, et al. (2005) Haematological changes in adults receiving a zidovudine-containing HAART regimen in combination with cotrimoxazole in Cote d'Ivoire. Antivir Ther 10: 615-624.
25. Lynen L, An S, Koole O, Thai S, Ros S, et al. (2009) An algorithm to optimize viral load testing in HIV-positive patients with suspected first-line antiretroviral therapy failure in Cambodia. J Acquir Immune Defic Syndr 52: 40-48.